Biogen Inc. (BIIB) is a leading biotechnology company valued at $22.1 billion, specializing in therapies for neurological diseases. Analysts predict a profit of $3.94 per share for fiscal Q3, down 3.4% from last year. For the year, EPS is expected to be $15.83, a 3.9% decrease. BIIB shares have fallen 19.5% over 52 weeks, underperforming the S&P 500 and XLV. After announcing Q2 results, shares rose 1.1% due to strong sales of MS therapies. Wall Street analysts have a “Moderate Buy” rating with a mean price target of $173.21, suggesting a 15.8% upside.

Read more at Yahoo Finance: What to Expect From Biogen’s Q3 2025 Earnings Report